Biotechnology

Edesa Biotech Reaches Enrollment Milestone in COVID Study

March 15, 2021 8:10 AM

TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 50% of the patients planned for the Phase 2 portion of its ongoing Phase 2/Phase 3 clinical study evaluating the company's EB05 drug candidate as a single-dose treatment for hospitalized COVID-19 patients with or...

Read more

Rapid Progress in Hypertension Studies by Lexaria

March 15, 2021 7:00 AM

Five studies underway to examine DehydraTECHTM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECHTM CBD as a treatment for hypertension. Three human clinical trials and two animal research trials are...

Read more

Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada

March 15, 2021 2:00 AM

Reduvo™ would be Canada's only DIN for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / March 15, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that the Dronabinol Soft Gel capsules New Drug Submission (NDS) file submitted to Health Canada on December...

Read more

Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial

March 15, 2021 2:00 AM

ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021 Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3 Clinical trial includes an interim analysis after 300 patients Separately, a global Phase 2-3 study in adults with mild to moderate symptoms is planned to be initiated in Q2 2021 Initial Phase 1 data support...

Read more

Experion and The Valens Company Enter into Pre-Roll Manufacturing Agreement

March 11, 2021 5:00 PM

VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) Canada's solution to craft cannabis supply and builder of premium cannabis brands including its sought after and popular brand Citizen Stash, is pleased to announce that it has entered into a custom pre-roll manufacturing agreement with The Valens Company (VLNS) (VLNCF) (the "Company," "The Valens...

Read more

Hillstream BioPharma Adds Leading Cancer Drug Development Executive and Features Hillstream's Quatramer-Based Ferroptosis Inducer, HSB-1216, in Two Abstracts Available for Viewing at AACR 2021 Annual Meeting

March 11, 2021 11:00 AM

Lynne A. Bui M.D., leading cancer drug development executive, joins Hillstream BioPharma's Board of Directors Abstracts highlight mechanistic and pharmacokinetic data from HSB-1216 in small cell lung cancer and in combination with ultra-low-dose chemotherapy in triple-negative breast cancer BRIDGEWATER, NJ / ACCESSWIRE / March 11, 2021 / Hillstream BioPharma, Inc. ("Hillstream") today announced that two abstracts highlighting the progress of...

Read more

ITOCO INC to Acquire Biotech Protocols and Technology Related to Carbon Credit Generation From ECAPFIN S.A.P.I. DE C.V

March 11, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / March 11, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that it has signed a purchase agreement with ECAPFIN S.A.P.I. De C.V. of Domicilio DISTRITO FEDERAL (Mexico City) Mexico, to acquire all the assets of the company which include: Bio Tech related to the growth and usage of the Nopal Cactus; Agreements to amalgamate Nopal Cactus Farms and related assets in Mexico and elsewhere for the purpose of...

Read more

Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

March 11, 2021 7:10 AM

Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is presenting and will be available to meet with investors...

Read more

American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

March 11, 2021 3:00 AM

EATONTOWN, NJ / ACCESSWIRE / March 11, 2021 / American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCell™), for use in its FDA approved IND Phase I Clinical Trial. The Company's autologous mesenchymal stem cell infusion therapy...

Read more

Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors

March 11, 2021 1:00 AM

Acknowledged innovation leader with deep scientific and business expertise in immunotherapy, oncology and infectious diseases ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 11, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Agnete Fredriksen, Ph.D., to the Company's Board of Directors...

Read more

Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting

March 10, 2021 5:00 PM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company's immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15,...

Read more

AdOM Advanced Optical Technologies Ltd. Announces the Launch of the Tear Film Imager (TFI) Device in the U.S.

March 10, 2021 10:45 AM

LOD, ISRAEL / ACCESSWIRE / March 10, 2021 / AdOM Advanced Optical technologies Ltd., a clinical and commercial stage ophthalmic medical device company, announces the launch of the Tear Film Imager (TFI) device in the U.S. The TFI is a non-invasive imaging device which is designed to simultaneously measure the muco-aqueous and lipid sublayers of the eye, at a dept resolution of nanometer level. It's use involves a brief 40 second exam per eye...

Read more

Biotech Medics, Inc. Provides A Company Update on The Company’s New Business Plan For 2021

March 10, 2021 9:00 AM

WOODLAND HILLS, CA / ACCESSWIRE / March 10, 2021 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that the firm has been making significant steps to transform BMCS into an new and more productive business model. Management is moving into the crypto space, an emerging growth marketplace. According to Anthony K. Miller, CEO, "as I mentioned before, we have been working diligently for over a year to make this change and we are now...

Read more

MJ Biotech, Inc. Submits Final Designs for CBD Extraction Facility, and A Second Foundation for Further Expansion

March 10, 2021 7:55 AM

CHEYENNE, WY / ACCESSWIRE / March 10, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), partner Genesis Botanical Research (GBR), is pleased to report they have broken ground on a second foundation which will be used to store hemp biomass. Plans for the structure arrived at GBR corporate offices, several contractors are currently placing. bids for the erection of the structure. Upon completion of this process plans will be submitted for official town...

Read more

GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

March 9, 2021 8:00 AM

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 9, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung cancer gene signatures. This new patent provides further...

Read more

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

March 9, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company's drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis (ACD), a potentially debilitating condition and occupational...

Read more

Vitro Biopharma Year ended October 31st, 2020 Financial Results of Operations and Shareholder Letter

March 9, 2021 6:00 AM

GOLDEN, CO / ACCESSWIRE / March 9, 2021 / Vitro Biopharma Inc. (formerly Vitro Diagnostics Inc.) (dba Vitro Biopharma), announced its year ended October 31st, 2020, financial results of operations. Vitro Biopharma recorded year ended October 31st, 2020 revenues of $ 648,708 vs $882,037 a decrease of 26% over the prior year directly attributed to the COVID-19 pandemic. Revenues in the fourth quarter of 2020 of $161,888 were up 23% over the...

Read more

Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers

March 9, 2021 1:00 AM

Initial findings show ensovibep to be safe and well tolerated with no significant adverse events Predictable exposure seen post administration, confirming the expected half-life of 2‑3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of...

Read more

OMNICANNA/Thermic Sciences Acquires 100% of Another European Groundbreaking Technology; Litcoat Electroluminescent Paint, Known as Multi-Colored Electrical Lighting Paint for Cars, Boats, Motorcycles, Billboards, Buildings, Houses, Bicycles, and So Much More

March 8, 2021 9:28 AM

NASHVILLE, TN / ACCESSWIRE / March 8, 2021 / Thermic Sciences International, former known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC PINK:ENDO), acquires another groundbreaking technology to adds to its growing list of acquisitions building strong towards its corporate conglomerate being coined as the latest North American powerhouse SPAC, 100% rights, assets and operations acquisition of Litcoat...

Read more

Correction To Tetra Bio-Pharma News Release Dated February 25th

March 8, 2021 9:00 AM

OTTAWA, ON / ACCESSWIRE / March 8, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP)(OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021. In the statement attributed to DanCann Pharma's CCO John Morell Frellsen, the estimate of peak sales by 2026 is cited at $55M DKK. In fact, the estimate of peak sales...

Read more